2015

10 Dec 2015 - 09:31

MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Oslo, December 10, 2015: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 125 000 shares at an average price of NOK 2,1495 per share. After registration of these shares Dr. Steiness has 1 805 954 shares and 100 000 warrants.

27 Oct 2015 - 11:35

Q3-2015 Interims results

Oslo, 27. October 2015. Serodus ASA (OAX:SER) announces its results for the third quarter 2015. 

21 Oct 2015 - 01:57

Invitation to a presentation of Q3 2015 results

Oslo – 21. October 2015 – Serodus ASA (Oslo Axess, SER) will present the Q3 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Tuesday 27 October 2015 at 08:00. The presentation will be held by CEO Eva Steiness and CFO Tore Kvam.

15 Sep 2015 - 03:00

REGISTRATION OF SHARE CAPITAL INCREASE

Reference is made to Serodus ASA's previous announcements regarding the result of its rights issue raising gross proceed of approximately NOK 25 million.

08 Sep 2015 - 10:30

FINAL RESULT AND ALLOCATION OF THE RIGHTS ISSUE

Reference is made to Serodus ASA's (the "Company") 
previous announcements regarding the rights issue of 
minimum 9,259,260 and maximum 11,111,111 new shares 
raising gross proceed of minimum NOK 25 million and 
maximum NOK 30 million (the "Rights Issue").

08 Sep 2015 - 08:30

DISCLOSURE OF HOLDINGS

Reference is made to Serodus ASA's (the "Company") previous announcements regarding the rights issue. The subscription period for Rights Issue and trading in the subscription rights expired on 3 September 2015 at 16:30.

04 Sep 2015 - 11:50

SERODUS ASA - PRELIMINARY RESULT OF THE RIGHTS ISSUE

Reference is made to Serodus ASA's (the "Company") 

previous announcements regarding the rights issue of 
minimum 9,259,260 and maximum 11,111,111 new shares 
raising gross proceed of minimum NOK 25 million and 
maximum NOK 30 million (the "Rights Issue").

September 2015 at 16:30.The subscription period for Rights Issue expired on 3

04 Sep 2015 - 08:00

SERODUS ASA: MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Oslo, September 4, 2015: Reference is made to the ongoing Rights issue, the Chairman of the board Svein Jacobsen has requested a purchase of 100 000 shares in the Rights issue at an price of NOK 2,70 per share through his wholly owned company Sveinja Invest AS.  He holds 54 621 subscription rights in the Right issue.

03 Sep 2015 - 05:10

Nikolai C. Brun joins Serodus

Serodus has today appointed Nikolai C. Brun as Vice President Drug Development. Dr. Brun is an MD, PhD from the University of Copenhagen and has an extensive experience from the pharmaceutical industry with a strong track record from clinical development.

14 Aug 2015 - 09:20

Q2-2015 results

Oslo, 14. August 2015. Serodus ASA (OAX:SER) announces its results for the second quarter 2015. 

11 Aug 2015 - 10:28

Invitation to a presentation of Q2 2015 results

Oslo – 11. August 2015 – Serodus ASA (Oslo Axess, SER) will present the Q2 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Friday 14 August 2015 at 08:30. The presentation will be held by CEO Eva Steiness and CFO Tore Kvam.

24 Jul 2015 - 12:21

Notice of Extraordinary General Meeting 17 August 2015

Oslo, (24. July 2015) Reference is made to the notification July 8th, 2015.  The extraordinary general meeting of Serodus ASA will be held on 17 August 2015 at 13:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meeting room Hagen 5.

09 Jul 2015 - 07:58

Contemplated rights issue

Oslo, 8. July 2015; Reference is made to Serodus ASA ("Serodus" or the "Company") quarterly report published on 24 April 2015 regarding the financing process. After evaluation of the Company’s financing requirements and alternatives, the Board of Directors (the "Board") of Serodus has resolved to propose an underwritten rights issue of minimum NOK 25 million and maximum NOK 30 million at a price of NOK 2.70 per share, with pre-emptive subscription rights for existing shareholders (the “Rights Issue”), to strengthen the Company's financial position. The Board will call for an extraordinary general meeting (the “EGM”) expected to be held on or about 17 August 2015 to resolve the Rights Issue.

30 Apr 2015 - 06:26

Notice of Annual General Meeting 21 May 2015

Oslo, (30.04.2015) The annual general meeting of Serodus ASA will be held on 21 May 2015 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 5.

28 Apr 2015 - 12:07

Peter Holm Tygesen joins Norwegian biotech company

Serodus today announced the appointment of Peter Holm Tygesen as Vice President Pharmaceutical Development. The company continues its actions moving forward to establish future partnerships.

16 Apr 2015 - 01:50

Serodus receive EMA approval

Oslo – April 2015 – Serodus ASA (Oslo Axess, SER) a Norwegian biotechnology company focused on developing novel innovative treatment within cardiovascular and metabolic diseases, today announced that the European Medicines Agency (EMA) has granted Serodus SME (Small and Medium Sized Business Entities) status.

14 Apr 2015 - 09:45

SER130 Acute Myocardial Infarction Patent allowed in Russia

Oslo, April 14, 2015: Serodus ASA (Oslo Axess: SER), a Norwegian biotech company, today announced that Russia’s Federal Service for Intellectual Property has granted to Serodus Patent No. 2011121971 titled, “IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases”.

09 Apr 2015 - 08:34

SERODUS ASA: STRENGTHENING OF MANAGEMENT TEAM

Oslo, April 09, 2015: Serodus ASA (Oslo Axess: SER) announces the strengthening of its management team with the employment of Jürgen Langhärig as Vice President, Business Development.

26 Feb 2015 - 10:41

SERODUS ASA: MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Oslo, February 26, 2015: Serodus ASA (Oslo Axess: SER) Tore Kvam (CFO) has today purchased 10 000 shares at an average price of NOK 2,80 per share through his wholly owned company Itza AS. After registration of these shares Tore Kvam owns 30 000 shares through his wholly owned company Itza AS.

12 Feb 2015 - 08:00

Serodus ASA: MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Oslo, February 12, 2015: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 45 898 shares at an average price of NOK 2,708 per share. After registration of these shares Dr. Steiness has 931 939 shares and 100 000 warrants.

13 Jan 2015 - 11:44

SERODUS ASA will present the company at the 7th annual Biotech Showcase in San Francisco

Oslo, January 12, 2014

Serodus ASA (Oslo Axess: SER) CEO, Eva Steiness will present Serodus to the 7th Annual Biotech Showcase conference in San Francisco Monday 12th of January 2015. The presentation will take place at 5PM at the Parc 55 Wyndham San Francisco Hotel. The slides from the presentation will be available in the Investor relations section of the company's website after the conference. Serodus will also have meetings with a spectrum of pharmaceutical companies with the purpose of having strategic discussions about the company's R&D portfolio.